News

G2G Wants Your Input to Contribute to New ARPA-H Initiative

The White House Office of Science & Technology Policy (OSTP) is establishing the framework for the Advanced Research Projects Agency-Health (ARPA-H) that was included in President Biden’s FY2022 budget. Modeled after the Defense Advanced Research Projects Agency (DARPA), ARPA-H would tackle bold challenges requiring large-scale, cross-sector coordination, employing a non-traditional and nimble approach to high-risk research. Specifically, under Director Eric Lander, PhD from the Broad Institute and MIT who was sworn in as the first Cabinet level Director of OSTP on June 2, 2021, ARPA-H will advance translational science and drive transformational health innovations that tackle gaps in the system and implement health breakthroughs.

G2G is participating in efforts to contribute input to help shape how ARPA-H will function and we would love to hear your thoughts and questions you would like us to address as we continue our dialogue with the OSTP and ARPA-H leadership.

Click here to provide G2G with your feedback.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights